Zacks Investment Research Upgrades Ra Pharmaceuticals (NASDAQ:RARX) to Hold

Zacks Investment Research upgraded shares of Ra Pharmaceuticals (NASDAQ:RARX) from a sell rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports.

According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

A number of other research firms also recently issued reports on RARX. Robert W. Baird started coverage on shares of Ra Pharmaceuticals in a report on Thursday, June 20th. They issued an outperform rating for the company. ValuEngine upgraded shares of Ra Pharmaceuticals from a buy rating to a strong-buy rating in a report on Tuesday, July 2nd. SunTrust Banks boosted their target price on shares of Ra Pharmaceuticals to $42.00 and gave the company a buy rating in a report on Friday, May 17th. Leerink Swann started coverage on shares of Ra Pharmaceuticals in a report on Wednesday, May 22nd. They issued an outperform rating and a $23.30 target price for the company. Finally, Svb Leerink started coverage on shares of Ra Pharmaceuticals in a report on Wednesday, May 22nd. They issued an outperform rating and a $33.00 target price for the company. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $37.73.

Ra Pharmaceuticals stock traded down $0.39 during trading on Thursday, reaching $32.59. The company had a trading volume of 687,681 shares, compared to its average volume of 471,840. Ra Pharmaceuticals has a 12-month low of $8.67 and a 12-month high of $36.96. The business’s 50 day moving average price is $30.78. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -15.82 and a beta of 1.23. The company has a quick ratio of 20.10, a current ratio of 20.10 and a debt-to-equity ratio of 0.02.

Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. Equities analysts expect that Ra Pharmaceuticals will post -1.8 earnings per share for the current year.

In other Ra Pharmaceuticals news, insider Simon Read sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $22.25, for a total transaction of $222,500.00. Following the completion of the sale, the insider now directly owns 8,521 shares in the company, valued at $189,592.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $33.10, for a total transaction of $350,694.50. Following the completion of the transaction, the insider now owns 8,521 shares of the company’s stock, valued at $282,045.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,452 shares of company stock valued at $970,463. 4.30% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in RARX. Group One Trading L.P. purchased a new position in shares of Ra Pharmaceuticals in the first quarter valued at $34,000. Legal & General Group Plc boosted its stake in shares of Ra Pharmaceuticals by 57.7% in the fourth quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock valued at $56,000 after purchasing an additional 1,121 shares during the period. Great West Life Assurance Co. Can purchased a new position in shares of Ra Pharmaceuticals in the fourth quarter valued at $63,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Ra Pharmaceuticals by 163.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,014 shares of the company’s stock valued at $68,000 after purchasing an additional 1,868 shares during the period. Finally, BNP Paribas Arbitrage SA purchased a new position in shares of Ra Pharmaceuticals in the first quarter valued at $88,000. Institutional investors and hedge funds own 95.16% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: What is a capital gains distribution?

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.